For patients with rosacea, recent research funded by the National Rosacea Society potentially identified a pathway for significant advances in the treatment of the disease. It is estimated that rosacea affects more than 16 million Americans.
The study, led by Anna Di Nardo, MD, PhD, associate professor of medicine of the University of California-San Diego and colleagues, examined whether cathelicidins, an antimicrobial peptide involved in the innate immune response that is over-produced in people with rosacea, were involved in spurring general transient receptor potential vanilloid 4 (TRPV) production. The researchers injected cathelicidins into mice bred to exhibit human-like rosacea symptoms, and saw significant increases in the expression of both TRPV2 and TRPV4 after 2 days. Additionally, researchers tested the findings in the laboratory (in vitro) in both mouse and human mast cell cultures, and confirmed that cathelicidin increases the expression of TRPV4 and also determining that TRPV4 regulates the inflammation caused by mast cells.
________________________________________________________________________
Related Content
New Approach for Diagnosis, Treatment of Rosacea
Alcohol Consumption Increases Rosacea Risk in Women
________________________________________________________________________
Based on the findings of the study, Dr Di Nardo and her team identified a protein receptor on mast cells, MRGX2, as the likely pathway to TRPV4 activation by cathelicidins. The team was able to prevent TRPV4 from reacting to cathelicidins by turning off MRGX2 in mast cells. This process prevented the mast cells from triggering an inflammatory immune response associated with rosacea.
“Although more work needs to be done, these findings suggest that potential therapies may be developed specifically to block TRPV4 as a direct means of treating or preventing inflammation in patients with rosacea,” Dr Di Nardo said. “We are grateful to the many rosacea patients whose donations to the NRS research grants program have made this effort possible.”
According to earlier research from Dr Di Nardo, mast cells, located at the interface between the nervous system and vascular system, were a “missing link” between rosacea triggers and inflammation. They study found that mast cells were a direct role in the activation of certain types of cathelicidins.
—Julie Gould (Mazurkiewicz)
For patients with rosacea, recent research funded by the National Rosacea Society potentially identified a pathway for significant advances in the treatment of the disease. It is estimated that rosacea affects more than 16 million Americans.
The study, led by Anna Di Nardo, MD, PhD, associate professor of medicine of the University of California-San Diego and colleagues, examined whether cathelicidins, an antimicrobial peptide involved in the innate immune response that is over-produced in people with rosacea, were involved in spurring general transient receptor potential vanilloid 4 (TRPV) production. The researchers injected cathelicidins into mice bred to exhibit human-like rosacea symptoms, and saw significant increases in the expression of both TRPV2 and TRPV4 after 2 days. Additionally, researchers tested the findings in the laboratory (in vitro) in both mouse and human mast cell cultures, and confirmed that cathelicidin increases the expression of TRPV4 and also determining that TRPV4 regulates the inflammation caused by mast cells.
________________________________________________________________________
Related Content
New Approach for Diagnosis, Treatment of Rosacea
Alcohol Consumption Increases Rosacea Risk in Women
________________________________________________________________________
Based on the findings of the study, Dr Di Nardo and her team identified a protein receptor on mast cells, MRGX2, as the likely pathway to TRPV4 activation by cathelicidins. The team was able to prevent TRPV4 from reacting to cathelicidins by turning off MRGX2 in mast cells. This process prevented the mast cells from triggering an inflammatory immune response associated with rosacea.
“Although more work needs to be done, these findings suggest that potential therapies may be developed specifically to block TRPV4 as a direct means of treating or preventing inflammation in patients with rosacea,” Dr Di Nardo said. “We are grateful to the many rosacea patients whose donations to the NRS research grants program have made this effort possible.”
According to earlier research from Dr Di Nardo, mast cells, located at the interface between the nervous system and vascular system, were a “missing link” between rosacea triggers and inflammation. They study found that mast cells were a direct role in the activation of certain types of cathelicidins.
—Julie Gould (Mazurkiewicz)
For patients with rosacea, recent research funded by the National Rosacea Society potentially identified a pathway for significant advances in the treatment of the disease. It is estimated that rosacea affects more than 16 million Americans.
The study, led by Anna Di Nardo, MD, PhD, associate professor of medicine of the University of California-San Diego and colleagues, examined whether cathelicidins, an antimicrobial peptide involved in the innate immune response that is over-produced in people with rosacea, were involved in spurring general transient receptor potential vanilloid 4 (TRPV) production. The researchers injected cathelicidins into mice bred to exhibit human-like rosacea symptoms, and saw significant increases in the expression of both TRPV2 and TRPV4 after 2 days. Additionally, researchers tested the findings in the laboratory (in vitro) in both mouse and human mast cell cultures, and confirmed that cathelicidin increases the expression of TRPV4 and also determining that TRPV4 regulates the inflammation caused by mast cells.
________________________________________________________________________
Related Content
New Approach for Diagnosis, Treatment of Rosacea
Alcohol Consumption Increases Rosacea Risk in Women
________________________________________________________________________
Based on the findings of the study, Dr Di Nardo and her team identified a protein receptor on mast cells, MRGX2, as the likely pathway to TRPV4 activation by cathelicidins. The team was able to prevent TRPV4 from reacting to cathelicidins by turning off MRGX2 in mast cells. This process prevented the mast cells from triggering an inflammatory immune response associated with rosacea.
“Although more work needs to be done, these findings suggest that potential therapies may be developed specifically to block TRPV4 as a direct means of treating or preventing inflammation in patients with rosacea,” Dr Di Nardo said. “We are grateful to the many rosacea patients whose donations to the NRS research grants program have made this effort possible.”
According to earlier research from Dr Di Nardo, mast cells, located at the interface between the nervous system and vascular system, were a “missing link” between rosacea triggers and inflammation. They study found that mast cells were a direct role in the activation of certain types of cathelicidins.
—Julie Gould (Mazurkiewicz)
